Navigation Links
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
Date:6/21/2009

prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI previously announced that its pivotal PIX 301 EXTEND trial of pixantrone had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14 of 70 patients (20.0%) for the pixantrone arm compared to four of 70 patients (5.7%) for the standard chemotherapy arm, p=0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission while on study.

The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections had a similar incidence in both study arms (18% vs. 13%). Although the grade 3, 4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a slightly higher incidence of serious cardiac disorders in patients treated with pixantrone than among patients who received comparator agents (8.8% vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and tachycardia.

In April 2009, CTI began a rolling submission of a New Drug Application (the "NDA") with the FDA for pixantrone to treat relapsed or refractory aggressive NHL. CTI expects to complete the submission this month and will request priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
5. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
6. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... BOSTON and NOTTINGHAM, England ... CBRX ) today announced that its subsidiary, ... to Clinical Trials platform at the annual CPhI/ICSE Worldwide ... which aims to support companies with the rapid development ... The new enabling technologies screening platform, which incorporates the ...
(Date:10/1/2014)... and NEW YORK , October 1, 2014 ... Organization (CRO) and service provider for the medical industries, announced today ... offices in New York City . genae Americas ... is strategically centered in one of the highest concentrations ... said Philippe Kassab , President at genae Americas. "The expansion ...
(Date:10/1/2014)... Oct. 1, 2014 Trovagene, Inc., (NASDAQ: ... today that Eli Diamond , MD, Assistant ... (MSK), presented clinical data from an ongoing study ... platform for the determination of oncogene mutational status ... The results were presented to both treating physicians ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3genae Opens Offices in New York City 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... CHICAGO, Nov. 16, 2010 New results from ... at the American Heart Association (AHA) Scientific Sessions ... (prasugrel) prior to coronary artery bypass graft surgery ... to patients treated with Plavix® (clopidogrel) (2.3 percent ...
... RIDGE, N.J., Nov. 16, 2010 Regado Biosciences, Inc., ... aptamers with active control agents, announced that Thomas J. ... abstract at the AHA Scientific Sessions meeting on November ... The abstract, entitled "RB006, a Direct Factor ...
Cached Medicine Technology:Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 2Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 3Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 4Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 5Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 6Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 2Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 3Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 4
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Join the more than 80 golfers who already ... ever charity golf tournament to benefit Project HEAL, a not-for-profit ... cannot afford treatment. The tournament will be held Monday, Oct. ... , The day-long event starts with 10:30 a.m. check-in and ... will begin at 5 p.m. and will include an auction ...
(Date:10/1/2014)... City, NJ (PRWEB) October 01, 2014 Diet ... with their intentions to lose weight and their dieting attempts ... unhealthy, fatty foods. Including hormone diet treatments into ... only allows patients to see fast and effective weight loss ... and begin forming healthy habits to maintain their weight for ...
(Date:10/1/2014)... Dar, Ethiopia, at the occasion of the Leishmaniasis ... 150 African and international leishmaniasis experts, results of ... efficacy monitoring plan, carried out by MSF, ... and Ethiopia, were presented to key decision makers ... of kala-azar with the combination of Sodium Stibogluconate ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2
... Marketer Spiegel Brands and Shasun USA, One of ... Producers of Ibuprofen, Have Signed Multi-Year ... Management,Services Inc., (OTC Bulletin Board: BPOM), a full-service ... today,announced that Spiegel Brands, Inc., Chicago, the women,s ...
... since 1998, announces recent additions to womenshealthchannel.com. These new features ... as teen pregnancy with each other and with ... ... (PRWEB) July 2, 2008 -- Womenshealthchannel.com , a physician-developed ...
... October 24-26, 2008 at the Catholic Institute in Toulouse, France. Investigators ... applications and prospective issues in an interactive and collaborative meeting from ... for details. , ... Carmel, IN (PRWEB) July 2, ...
... clinicians should understand and consider the economic impact of ... a report appearing in the July/August issue of ... journal of the American Cancer Society. The report says ... clinicians to be aware of the relative costs and ...
... equivalent of 300 human genomes in just over six months. ... letters of genetic code that will be read by researchers ... health and disease. Scientists will be able to answer questions ... will be transformed. , The amount of data is ...
... Health,Systems, Inc. (Amex: ADK ), an Ohio based ... the refinancing of three assisted,living properties in Ohio., ... assisted living,properties located in Springfield, Ohio and Hearth & ... property located in Urbana, Ohio.,Both entities are limited liability ...
Cached Medicine News:Health News:BPO Management Services Wins Two New Information Technology Outsourcing Contracts 2Health News:BPO Management Services Wins Two New Information Technology Outsourcing Contracts 3Health News:Womenshealthchannel Enhancements Support Pregnant Teens 2Health News:Womenshealthchannel Enhancements Support Pregnant Teens 3Health News:Womenshealthchannel Enhancements Support Pregnant Teens 4Health News:Womenshealthchannel Enhancements Support Pregnant Teens 5Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 3Health News:Report says clinicians should consider economic impact of new interventions 2Health News:15 human genomes each week 2Health News:15 human genomes each week 3Health News:AdCare Health Systems, Inc. Announces the Refinancing of Three Assisted Living Properties in Ohio 2
... fully automated genetic analysis system. This system ... patented linear polyacrylamide (LPA) gel, denatures and ... and analyzes the data. Software tools let ... customize automated data assessment. All to ensure ...
The ABL77 is always ready to use. No manual cassette preparation or calibration necessary prior to testing. Portable with battery. For both high and low volume testing....
... Rapidlab 800 System is a fully automated, ... care whole blood parameters in addition to ... allows the basic blood gas model to ... electrolytes, metabolites and CO-oximetry in a single ...
... Sorvall Discovery 90SE Ultracentrifuge ... to discover more. All ... with top-of-the-line performance, powerful ... of use, all built ...
Medicine Products: